|
Lab based lateral flow assay to detect the presence of Methicillin Resistant and Methicillin Sensitive Staphylococcus aureus in blood
|
0.34
|
6
|
Hazardous Medical/Clinical/Infectious Waste (HMCIW)
|
|
In vitro lab based diagnostic test kit for detection and genotyping warfarin metabolism
|
0.36
|
3
|
HMCIW
|
|
In vitro lab based diagnostic test kit for detection of single nucleotide polymorphism to detect risk from venous thrombosis
|
1
|
3
|
HMCIW
|
|
OTC pregnancy and ovulation test kits to detect hormones in urine
|
3–100
|
20–460
|
Municipal solid waste
|
|
Lab based in vitro rapid test kits for qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and blood
|
2–80
|
20–830
|
HMCIW
|
|
Home based in vitro HIV test kits
|
20
|
90
|
Municipal solid waste
|
|
Lab based in vitro tests for detection of CD4 cells and viral loads for HIV patients
|
60
|
540
|
HMCIW
|
|
Lab based diagnostic test kits for infectious diseases
|
70
|
350
|
HMCIW
|
|
Removal of Staphylococcus aureus from the nasal passage of patients to reduce risks of nosocomial infections
|
30–53,300
|
110–164,640
|
HMCIW
|
|
Treatment of periodontitis
|
270–106,560
|
940–365,160
|
Waste water
|
|
Sensors for diagnosing diseases from breath samples
|
0.01–1590
|
0.03–4620
|
HMCIW
|
|
Treatment for solid tumors (colorectal, pancreas, breast)
|
70 -(480) -1100
|
310-(2020)–4600
|
Waste water
|
|
Last line treatment for patients with solid tumors (colorectal, pancreatic and breast)
|
420
|
1500
|
Waste water
|
|
Treatment for patients diagnosed with head and neck and lung cancer
|
140,290–233,820
|
744,750–1,241,260
|
Waste water
|
|
Last line treatment for patients with head and neck and lung cancer
|
104,710–174,520
|
468,250–780,410
|
Waste water
|
|
Transbuccal insulin delivery platforms
|
128,250
|
841,620
|
Waste water
|
